[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:dnmt3a-gene":3},{"name":4,"total":5,"recruiting":5,"trials":6},"DNMT3A Gene",3,[7,15,22],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05641831","Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study",[11],"Phase 2","RECRUITING","2026-08-26T02:15:45.413021Z","2026-05-05T02:43:29.648361Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT06313437","Revumenib in Combination With 7+3 + Midostaurin in AML",[19],"Phase 1","2026-08-26T02:16:56.877406Z","2026-05-05T02:43:28.835411Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT03418038","Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia",[11],"2026-08-26T02:15:21.365312Z","2026-05-05T02:43:29.732946Z"]